PDF(Pubmed)
Abstract：
UNASSIGNED: Although Remdesivir has been evaluated for the treatment of coronavirus disease 2019 (COVID-19), few study has yet shown effective mortality reduction. It might be because, in almost all those studies, remdesivir therapy was started beyond 7th days from the onset of symptoms when the active viral replications have already gone.
UNASSIGNED: This study reviewed the effectiveness of early remdesivir therapy during viral phase of COVID-19 and safety of its administration at home or community care during the outbreak of COVID-19 from July to September 2021 in Myanmar. We retrospectively reviewed clinical records of 204 high risk COVID-19 patients who had received remdesivir therapy within 7 days from the onset of illness and before oxygen desaturation.
UNASSIGNED: All patients received remdesivir therapy according to standard five days course of 200 mg loading dose on day 1, followed by 100 mg daily for up to 4 additional days. Out of 204 patients, 60.75% (124/204) were aged 60 years and above with comorbidity; 21.1% (43/204) aged under 60 years with comorbidity and 18.1% (37/204) were aged more than 60 years old without comorbidity. The patients who received RDSV therapy within 1-4 days and within 5-7 days were 50.5% (103/204) and 49.5% (101/204) respectively. All patients survived to 21 days without ICU admission or mechanical ventilation. Eighty six percent of patients had no hypoxia and only five percent had moderate to severe hypoxia, requiring oxygen. Those who received RDSV therapy within 1 to 4 days from the onset of symptoms had significantly lower rate of hypoxia compared to those who received remdesivir therapy on 5 to 7 days. After RDSV therapy, increased lymphocyte count and decreased CPR were observed in 74.5% (152/204) and 52.9% (108/204) of the patients respectively. There was no report of major adverse events.
UNASSIGNED: Remdesivir, if given within first 4 days from the onset of symptoms, is the most effective strategy for prevention of oxygen desaturation, further progression of COVID-19 and death although it is still beneficial if given later, days 5 to 7. It is a safe drug to be prescribed in hospital at home care. It may be cost-benefit if high-risk group of patients with COVID-19 were selected for early remdesivir therapy in the community.
UNASSIGNED: This study reviewed the effectiveness of early remdesivir therapy during viral phase of COVID-19 and safety of its administration at home or community care during the outbreak of COVID-19 from July to September 2021 in Myanmar. We retrospectively reviewed clinical records of 204 high risk COVID-19 patients who had received remdesivir therapy within 7 days from the onset of illness and before oxygen desaturation.
UNASSIGNED: All patients received remdesivir therapy according to standard five days course of 200 mg loading dose on day 1, followed by 100 mg daily for up to 4 additional days. Out of 204 patients, 60.75% (124/204) were aged 60 years and above with comorbidity; 21.1% (43/204) aged under 60 years with comorbidity and 18.1% (37/204) were aged more than 60 years old without comorbidity. The patients who received RDSV therapy within 1-4 days and within 5-7 days were 50.5% (103/204) and 49.5% (101/204) respectively. All patients survived to 21 days without ICU admission or mechanical ventilation. Eighty six percent of patients had no hypoxia and only five percent had moderate to severe hypoxia, requiring oxygen. Those who received RDSV therapy within 1 to 4 days from the onset of symptoms had significantly lower rate of hypoxia compared to those who received remdesivir therapy on 5 to 7 days. After RDSV therapy, increased lymphocyte count and decreased CPR were observed in 74.5% (152/204) and 52.9% (108/204) of the patients respectively. There was no report of major adverse events.
UNASSIGNED: Remdesivir, if given within first 4 days from the onset of symptoms, is the most effective strategy for prevention of oxygen desaturation, further progression of COVID-19 and death although it is still beneficial if given later, days 5 to 7. It is a safe drug to be prescribed in hospital at home care. It may be cost-benefit if high-risk group of patients with COVID-19 were selected for early remdesivir therapy in the community.
摘要：
未经批准：尽管已对Remdesivir治疗2019年冠状病毒病（COVID-19）进行了评估，很少有研究显示有效降低死亡率。可能是因为,在几乎所有这些研究中，当活跃的病毒复制已经消失时,在症状出现后第7天开始雷米西韦治疗.
UNASSIGNED：本研究回顾了在2021年7月至9月缅甸COVID-19爆发期间，早期雷德西韦治疗在COVID-19病毒期的有效性以及在家庭或社区护理中使用的安全性。我们回顾性分析了204例高危COVID-19患者的临床记录，这些患者在发病后7天内和氧饱和度之前接受了雷西韦治疗。
UNASSIGNED：所有患者在第1天接受了200mg负荷剂量的标准五天疗程的remdesivir治疗，然后每天100mg，持续4天。在204名患者中，60岁及以上有合并症的占60.75%(124/204)；60岁以下有合并症的占21.1%(43/204)，60岁以上无合并症的占18.1%(37/204)。在1-4天内和5-7天内接受RDSV治疗的患者分别为50.5%(103/204)和49.5%(101/204)。所有患者均存活至21天，无需ICU入住或机械通气。86％的患者没有缺氧，只有5％的患者有中度至重度缺氧，需要氧气。与在5至7天接受remdesivir治疗的患者相比，在症状发作后1至4天内接受RDSV治疗的患者的缺氧率显着降低。RDSV治疗后,淋巴细胞计数增加和CPR减少分别在74.5%(152/204)和52.9%(108/204)的患者中观察到.没有重大不良事件的报告。
未经批准：Remdesivir，如果在症状出现后的前4天内给予，是预防氧饱和度降低的最有效策略,COVID-19的进一步进展和死亡，尽管如果以后给药仍然是有益的，第5至7天这是一种安全的药物，可以在医院的家庭护理中处方。如果选择COVID-19患者的高危人群在社区进行早期雷米西韦治疗，可能会带来成本效益。
UNASSIGNED：本研究回顾了在2021年7月至9月缅甸COVID-19爆发期间，早期雷德西韦治疗在COVID-19病毒期的有效性以及在家庭或社区护理中使用的安全性。我们回顾性分析了204例高危COVID-19患者的临床记录，这些患者在发病后7天内和氧饱和度之前接受了雷西韦治疗。
UNASSIGNED：所有患者在第1天接受了200mg负荷剂量的标准五天疗程的remdesivir治疗，然后每天100mg，持续4天。在204名患者中，60岁及以上有合并症的占60.75%(124/204)；60岁以下有合并症的占21.1%(43/204)，60岁以上无合并症的占18.1%(37/204)。在1-4天内和5-7天内接受RDSV治疗的患者分别为50.5%(103/204)和49.5%(101/204)。所有患者均存活至21天，无需ICU入住或机械通气。86％的患者没有缺氧，只有5％的患者有中度至重度缺氧，需要氧气。与在5至7天接受remdesivir治疗的患者相比，在症状发作后1至4天内接受RDSV治疗的患者的缺氧率显着降低。RDSV治疗后,淋巴细胞计数增加和CPR减少分别在74.5%(152/204)和52.9%(108/204)的患者中观察到.没有重大不良事件的报告。
未经批准：Remdesivir，如果在症状出现后的前4天内给予，是预防氧饱和度降低的最有效策略,COVID-19的进一步进展和死亡，尽管如果以后给药仍然是有益的，第5至7天这是一种安全的药物，可以在医院的家庭护理中处方。如果选择COVID-19患者的高危人群在社区进行早期雷米西韦治疗，可能会带来成本效益。
